Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.

ABSTRACT:

Importance

Clinical trials testing treatments for Alzheimer disease (AD) are increasingly focused on cognitively normal individuals in the preclinical phase of the disease. To optimize observing a treatment effect, such trials need to enroll cognitively normal individuals likely to show cognitive decline over the duration of the trial.

Objective

To identify which group of cognitively normal individuals shows the greatest cognitive decline over time based on their cerebrospinal fluid biomarker profile.

Design, setting, and participants

In this cohort study, cognitively normal participants were classified into 1 of the following 4 hypothetical preclinical AD groups using baseline cerebrospinal fluid levels of Aβ and tau or Aβ and phosphorylated tau (p-tau): stage 0 (hig

SUBMITTER: Soldan A 

PROVIDER: S-EPMC5173327 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature